Pegsebrenatide

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NamePegsebrenatide
Drug Alias NamePegylated exenatide4G-PEG exenatideOlaedinNLY-01NLY01-D +[10] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Parkinson DiseaseMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeuraly Inc
China Registration ClassN/A

Develop Information

Active CompaniesJohns Hopkins UniversityNeuraly IncD&D Pharmatech
Inactive CompaniesN/A
Active IndicationsParkinson DiseaseMultiple Sclerosis
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A